Pathogen | Nonsusceptibility phenotype | Overall, % NS (n/N) | Prior antibiotic exposure | ||
---|---|---|---|---|---|
0 | 1 | ≥2 | |||
Escherichia coli (n = 3013)a,b | Fluoroquinolone-NS | 25.4 (758/2990) | 25.5 (482/1888) | 24.8 (253/1020) | 28.0 (23/82) |
Third-generation cephalosporin-NS | 3.5 (105/3013) | 3.8 (72/1903) | 2.7 (28/1028) | 6.1 (5/82) | |
MDR | 23.4 (705/3013) | 24.1 (458/1903) | 21.6 (222/1028) | 30.5 (25/82) | |
Carbapenem-NS | 0.1 (4/3006) | 0.2 (3/1900) | 0.1 (1/1025) | 0 (0/81) | |
Piperacillin/tazobactam-NS | 4.4 (131/2965) | 4.6 (86/1871) | 4.1 (42/1014) | 3.8 (3/80) | |
Klebsiella pneumoniae (n = 1039)a,c | Fluoroquinolone-NS | 6.8 (70/1036) | 6.0 (41/689) | 7.5 (24/320) | 18.5 (5/27) |
Third-generation cephalosporin-NS | 3.7 (38/1039) | 2.7 (19/692) | 5.0 (16/320) | 11.1 (3/27) | |
MDR | 10.1 (105/1039) | 9.2 (64/692) | 11.3 (36/320) | 18.5(5/27) | |
Carbapenem-NS | 1.5 (16/1035) | 1.0 (7/690) | 2.5 (8/319) | 3.8 (1/26) | |
Piperacillin/tazobactam-NS | 7.1 (73/1021) | 6.0 (41/685) | 9.4 (29/310) | 11.5 (3/26) | |
Pseudomonas aeruginosa (n = 502)a,d | Fluoroquinolone-NS | 21.8 (109/499) | 22.2 (70/316) | 20.6 (33/160) | 26.1 (6/23) |
Third-generation cephalosporin-NS | 8.8 (44/502) | 10.4 (33/318) | 5.0 (8/161) | 13.0 (3/23) | |
MDR | 8.8 (44/502) | 10.4 (33/318) | 5.0 (8/161) | 13.0 (3/23) | |
Carbapenem-NS | 7.3 (36/496) | 7.3 (23/314) | 5.7 (9/159) | 17.4 (4/23) | |
Piperacillin/tazobactam-NS | 4.0 (20/494) | 4.1 (13/314) | 4.4 (7/158) | 0 (0/22) | |
Other Enterobacteriaceae (n = 1539)a,e | Fluoroquinolone-NS | 14.1 (216/1531) | 14.5 (137/947) | 13.9 (74/534) | 10.0 (5/50) |
Third-generation cephalosporin-NS | 3.9 (60/1539) | 4.0 (38/953) | 3.9 (21/536) | 2.0 (1/50) | |
MDR | 27.6 (424/1539) | 26.4 (252/953) | 29.9 (160/536) | 24.0 (12/50) | |
Carbapenem-NS | 1.5 (23/1525) | 1.5 (14/944) | 1.7 (9/532) | 0 (0/49) | |
Piperacillin/tazobactam-NS | 4.9 (75/1529) | 4.8 (45/947) | 5.4 (29/533) | 2.0 (1/49) |